

PUBLICATIONS AND ABSTRACTS FOR DR. KRISTINE (PEK LING) NG

ABSTRACTS/CONFERENCE PROCEEDINGS/PRESENTATIONS

1. Kalluru R, Wilsher ML, Milne D, **Ng Kristine P.** Prevalence of autoantibodies in idiopathic inflammatory myopathy and/or interstitial pneumonia. **New Zealand Rheumatology Association/NZHRPR Annual Scientific Meeting.** 1-4 Aug 2013. Hamilton, New Zealand.
2. Wilsher ML, Kalluru R, Milne D, **Ng Kristine P.** Prevalence of autoantibodies in idiopathic inflammatory myopathy and/or interstitial pneumonia. **6th International WASOG conference on Diffuse Parenchymal Lung Diseases.** 6-7 June 2013. Paris, France.
3. Kalluru R, **Ng Kristine P,** Corkill M, Hart H. Retrospective audit of Idiopathic Inflammatory Myositis patients in Waitemata DHB. **New Zealand Rheumatology Association/NZHRPR Annual Scientific Meeting.** Aug 2011. Auckland, New Zealand.
4. Ghosh S, Corkill M, Hart H, **Ng Kristine P.** Screening for Pulmonary Arterial Hypertension in patients with scleroderma – NZ perspective. **New Zealand Rheumatology Association/NZHRPR Annual Scientific Meeting.** Aug 2011. Auckland, New Zealand.
5. T.Y. Lu, **K. P. Ng,** G. Cambridge, M.J. Leandro, M. Ehrenstein, J.C. Edwards, D.A. Isenberg. A retrospective seven year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first 50 patients. **New Zealand/Australian Rheumatology Association Meeting.** May 2009. Wellington, New Zealand
6. D.A. Isenberg, T.Y. Lu, **K. P. Ng,** G. Cambridge, M.J. Leandro, M. Ehrenstein, J.C. Edwards. A retrospective seven year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first 50 patients. **72nd American College of Rheumatology ACR/ARHP Annual Scientific Meeting.** 24-29 Oct 2008. San Francisco, USA. Abstract 1075.
7. Tim Y. Lu, **Kristine P. Ng,** Geraldine Cambridge, Maria J. Leandro, Jonathan C. Edwards and David A. Isenberg. A retrospective seven year analysis of the use of B cell depletion therapy in Systemic Lupus Erythematosus at University College London Hospital: The first fifty patients. **British Society of Rheumatology Annual Meeting.** 22-25 April 2008. Liverpool, UK. Abstract 33. **Rheumatology** 47(Supplm 2) ii1.
8. **K. P. Ng,** G. Cambridge, M.J. Leandro, J.C. Edwards, M. Ehrenstein, D.A. Isenberg. B cell depletion therapy in patients with systemic lupus erythematosus: long term follow up and predictors of response. **European Congress of Rheumatology (EULAR)** 13-16 June 2007, Barcelona, Spain. **Ann Rheum Dis** 2007;66(Suppl II):56
9. **K. P. Ng** Acquired Inflammatory Muscle Disease. Presentation at the **Neuromuscular course.** 21 May 2007. University College London, Institute of Neurology, Queens Square, London, UK
10. **K. P. Ng,** C. Smith and D. A. Isenberg. But is it really an inflammatory myopathy?, **British Society of Rheumatology Annual Meeting** 8 - 11 May 2007, Birmingham, UK. Abstract 362. **Rheumatology** 46(Supplm 1). i36.

11. **Kristine P. Ng**, Filipa Ramos, Shabina Sultan, David A. Isenberg. Concomitant diseases in a cohort of patients with idiopathic myositis during long term follow up. **70th American College of Rheumatology ACR/ARHP Annual Scientific Meeting**. November 2006. Washington DC, United States. Abstract 1651.
12. **Kristine P. Ng**, Maria J. Leandro, Jonathan C. Edwards, Geraldine Cambridge, David A. Isenberg. Long term follow up of patients with systemic lupus erythematosus (SLE) after B cell depletion. **70th American College of Rheumatology ACR/ARHP Annual Scientific Meeting**. November 2006. Washington DC, United States. Abstract 536.
13. **K. P. Ng**. Update on rituximab. Invited speaker to the SLE special interest group meeting. **British Society of Rheumatology Annual Meeting**. 2 - 5 May 2006, Glasgow, Scotland.
14. **K. P. Ng**, J. J. Manson, A. Rahman and D. A. Isenberg. Association of Anti-nucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. **British Society of Rheumatology Annual Meeting**. 2 - 5 May 2006, Glasgow, Scotland. Abstract 428. **Rheumatology** 45(Supplm 1). i164.
15. **K. P. Ng**, F. Ramos, S. M. Sultan and D. A. Isenberg. Concomitant disease in a cohort of patients with idiopathic myositis during long term follow up. **British Society of Rheumatology Annual Meeting**. 2 - 5 May 2006, Glasgow, Scotland. Abstract 408. **Rheumatology** 45(Supplm 1). i157.
16. S. M. Sultan, E. Allen, P. Kiely, **K. Ng** and D. A. Isenberg. Further Inter-rater Reliability and Validity Assessment Of The Myositis Disease Activity Assessment Tool (MDAAT) Following Modification Of The Original Tool. **British Society of Rheumatology Annual Meeting**. 2 - 5 May 2006, Glasgow, Scotland. Abstract 409. **Rheumatology** 45(Supplm 1). i158.
17. **K. P. Ng**, G. Cambridge, M.J. Leandro, J.C. Edwards, M. Ehrenstein, D.A. Isenberg. Repeated B cell depletion in treatment of refractory SLE”, **69th American College of Rheumatology ACR/AHRP Annual Scientific Meeting**, 12-17 November 2005. San Diego, California, United States. Abstract 449.
18. **K. P. Ng**, J. J. Manson, A. Rahman and D. A. Isenberg. Association of anti-nucleosome antibodies with disease flare in Serological Active Clinical Quiescent SLE patients. **69th American College of Rheumatology ACR/AHRP Annual Scientific Meeting**. 12-17 November 2005. San Diego, California, United States. Abstract 405.
19. **K. P. Ng**, G. Cambridge, M.J. Leandro, J.C. Edwards, M. Ehrenstein, D.A. Isenberg. Repeated B cell depletion in treatment of refractory SLE. Invited speaker at the **Rheumatology London Research Group meeting** 2005.
20. **Ng KP**, Austin P, Ameratunga R, McQueen FM. Clinical use of anti CCP2 assay in Rheumatoid Arthritis. **46th Australian Rheumatology Association Scientific Conference**. May 2004. Cairns, Australia. **Intern Med J** 2004 Nov;34(11):A103.
21. **Ng KP**, Gow P. Gout and renal failure. **New Zealand Rheumatology Association Annual Scientific Meeting**. September 2004. Auckland, New Zealand
22. **Ng KP**, McQueen FM. Behcet’s disease. **New Zealand Rheumatology Association ASM/IMANZ/RACP Annual Conference**. September 2003. Rotorua, New Zealand

PUBLICATIONS

1. Ghosh S, Corkill M, Hart H, **Ng KP**. Screening for pulmonary arterial hypertension in patients with scleroderma – a New Zealand perspective. **N Z Med J** 2014 Aug15;127(1400):30-8
2. **Ng KP**, Ramos F, Sultan SM, Isenberg DA. Concomitant diseases in a cohort of patients with idiopathic myositis during long term follow up. **Clin Rheum** 2009; 28:947-53
3. Lu TY, **Ng KP**, Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein M, Isenberg DA. A Retrospective Seven - Year Analysis of the use of B cell depletion therapy in Systemic Lupus Erythematosus at University College London Hospital. **Arthritis & Rheumatism** 2009 Mar 30;61(4):482-487. [Epub ahead of print]
4. **Ng KP** Clinician's corner: Challenges in diagnosing and treating Sjogren's in the older patient; **Sjogren's Quarterly** (Vol 2 – Issue 2 Spring 2009) for the Sjogren's Syndrome Foundation USA
5. Sultan SM, **Ng KP**, Edwards JCW, Isenberg D, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. **Clinical and Experimental Rheumatology** 2008 Sep-Oct;26(5):887-93
6. Lu TY, **Ng KP**, Isenberg DA. Inflammatory muscle disease assessment. **Current Rheumatology Reports** 2008 Aug;10(4):328-32
7. **Ng KP**, Isenberg DA. Sjogren's syndrome: Diagnostic and Therapeutic Challenges in the Elderly. **Drugs & Aging** 2008; 25(1):19-33
8. **Ng KP**, Isenberg DA. Anti CD20 to further targeted therapies in rheumatology. In: Smolen JS, Lipsky PE, eds. **Contemporary Targeted Therapies in Rheumatology**. Informa Healthcare UK, Oct 2007: 509-526
9. **Ng KP**, Smith CR, Isenberg DA. Muscular dystrophy mimicking refractory idiopathic inflammatory myositis: A trio of cases. **Rheumatology (Oxford)** 2007 Oct; 46(10):1618-9. Epub 2007 Aug 17

10. **Ng KP**, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: Long term follow up and predictors of response. **Annals of the Rheumatic Diseases**. 2007 Sep; 66(9):1259-1262. Epub 2007 Apr 5.
11. **Ng KP**, Gow PJ. Management of scleroderma in a New Zealand tertiary rheumatology centre: emphasis on pulmonary complications. **New Zealand Medical Journal** 2007 May 18; 120 (1254): U2537
12. **Ng KP**, Manson JJ, Rahman A, Isenberg DA. Association of anti-nucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. **Arthritis & Rheumatism** 2006 Dec 15; 55(6):900-04
13. **Ng KP**, Austin P, Ameratunga R, McQueen FM. Role of anti cyclic citrullinated peptide 2 assay in long standing rheumatoid arthritis. **APLAR Journal of Rheumatology** 2006 Sept; 9(3):211-15
14. **Ng KP**, Leandro MJ, Edwards JCW, Ehrenstein M, Cambridge G, Isenberg D. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. **Annals of the Rheumatic Diseases** 2006 July; 65(7): 942-945. Epub 2005 Nov 3.
15. **Ng KP**, Doube A. Stroke after neck manipulation in the post partum period. **New Zealand Medical Journal** Nov 2001; Vol 114: 1143